Outlook Therapeutics Says UK MHRA Grants Marketing Authorization For LYTENAVA To Treat Wet AMD

Biopharmaceutical company Outlook Therapeutics, Inc. (OTLK) announced Monday that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for LYTENAVA (bevacizumab gamma). LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU and UK. This approval comes after Outlook...

Read More

Crypto Theft Plummets by 48% in March — Are Crypto Assets Getting Safer?

March saw a major decrease in crypto theft incidents, with malicious actors stealing approximately $79 million from decentralized finance (DeFi) projects, according to data from blockchain security firm CertiK. The figure represents an incredible 48% drop compared to the $160 million stolen in February. Flash Loan Attacks and Phishing Scams Contribute to Losses CertiK’s breakdown...

Read More

Madrigal Pharmaceuticals upsizes public offering to $600 million

CONSHOHOCKEN, Pa. - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a company specializing in treatments for nonalcoholic steatohepatitis (NASH), has upsized its public offering to $600 million, the firm announced Monday. The offering, originally set at $500 million, was increased by $100 million following strong investor interest. The company is offering 750,000 shares of common stock at $260...

Read More